Bio-Rad Laboratories (BIO) News
NYSE: BIOIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
366.16+5.76 (+1.60%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BIO news summary
We found 3 recent headlines mentioning Bio-Rad Laboratories (BIO): 0 in the past week and 2 in the past 30 days, most often from Nasdaq. For price context, BIO is up 1.60% at $366.16. The most recent story, "Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests", was published by Nasdaq on Sep 28, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Bio-Rad Laboratories headlines
- Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive TestsBDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.NasdaqBDSX, TMO, BIO, VCYT
- Biodesix Reveals Two Developing MRD Solution Collaborations With Bio-Rad And Thermo Fisher(RTTNews) - Biodesix Inc. (BDSX), a diagnostic solutions company, last week reported strategic progress for two programmes regarding Molecular Residual Disease (MRD) solutions for cancer diagnosis.…NasdaqBDSX, BIO, TMO
- Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.NasdaqBIO, DHR, TECH